S. Stick (Perth, Australia), G. Davies (London, United Kingdom)
Effects of the CFTR potentiator, ivacaftor, in two phase 3 trials in subjects with CF who have the G551D-CFTR mutation
J.S. Elborn, C. Wainwright, I. Sermet-Gaudelus, S. Rodriguez, K. Yen, B. Ramsey (Belfast, United Kingdom; Brisbane, Australia; Paris, France; Cambridge, Seattle, United States Of America)
|   |
Effect of ivacaftor on lung clearance index and FEV1 in subjects with CF who have the G551D-CFTR mutation and mild lung disease
F. Ratjen, H. Sheridan, P.S. Lee, T. Song, A. Stone, J. Davies (Toronto, Canada; London, United Kingdom; Cambridge, United States Of America)
| |
Long-term safety and efficacy of ivacaftor in subjects with CF who have the G551D-CFTR mutation
E. McKone, S. Rodriguez, K. Yen, J. Davies (Dublin, Ireland; Cambridge, United States Of America; London, United Kingdom)
| ![]()  ![]() |
Inhaled glutathione tolerability and efficacy in patients with cystic fibrosis
C. Calabrese, V. Raia, V. Carnovale, P. Abete, A. Tosco, A. Magliocca, A. Casale, C. Basile, P. De Fazio, C.M.E. Tranfa (Naples, Italy)
| |
Assessment of lung function in pre-school children with cystic fibrosis by nitrogen washout
J. Zirbes, D. Prais, C. Dunn, C. Milla (Palo Alto, United States Of America; Petach Tikvah, Israel)
| ![]() ![]() |
Alternative multiple breath washout outcomes for clinical trials in cystic fibrosis
F. Ratjen, J. Salazar, R. Jensen, R. Amin, P. Gustafsson, S. Stanojevic, P. Subbarao (Toronto, Canada; Skoevde, Sweden)
| |
Evaluation of the peripheral airway microstructure in children with cystic fibrosis (CF) using 3He magnetic resonance imaging
E. Gaillard, I. Ball, K. Panesar, N. Al-Khathlan, M. Narayanan, C. Beardsmore, J. Owers-Bradley (Leicester, United Kingdom)
| |